Rybelsus and SNRIs (Venlafaxine, Duloxetine): Drug Interaction Guide

Does either label list the other drug?

Rybelsus is oral semaglutide, a GLP-1 receptor agonist approved to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for them [1]. It has no weight-loss indication [1]. The tablet is co-formulated with SNAC, an absorption enhancer that helps semaglutide be absorbed, mainly in the stomach [1].

Venlafaxine (Effexor XR) is labeled for major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder in adults [2]. Duloxetine is labeled for major depressive disorder, generalized anxiety disorder in adults and children aged 7 and older, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain [3]. A person with type 2 diabetes may take Rybelsus for glucose control and duloxetine for diabetic nerve pain [1][3].

The Rybelsus drug interactions section covers two situations: insulin secretagogues such as sulfonylureas, and insulin, because of hypoglycemia risk; and other oral drugs, because semaglutide delays gastric emptying [1]. The venlafaxine label's interaction table covers MAOIs, other serotonergic drugs, drugs that interfere with hemostasis, CYP3A inhibitors and CYP2D6 substrates, with separate notes on CNS-active drugs and weight-loss agents [2]. The duloxetine label's interaction material centers on CYP1A2 inhibitors, CYP2D6 inhibitors, drugs cleared by CYP2D6, and added bleeding or serotonergic risk [3]. None of these descriptions includes the pair, and no study of Rybelsus together with venlafaxine or duloxetine is described in them.

The 30-minute instruction

The Rybelsus label's administration instructions are specific [1]:

• Take one tablet once a day in the morning on an empty stomach with up to 4 ounces of plain water, and do not take it with other liquids.
• Swallow tablets whole; do not split, crush, chew or dissolve them.
• Do not take more than one tablet per day.
• After taking the tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications. That includes an oral SNRI.
• If a dose is missed, skip it and take the next dose the following day.

The label gives the starting, escalation and maintenance steps as a way to reduce the risk of gastrointestinal adverse reactions: 3 mg for 30 days (not effective for glycemic control), 7 mg on days 31 to 60, then 7 mg or 14 mg from day 61 [1].

Semaglutide delays gastric emptying and may affect the absorption of other oral drugs [1]. In a drug interaction study, levothyroxine exposure was 33% higher (90% CI 1.25 to 1.42) when given with semaglutide tablets [1].

Could Rybelsus change SNRI levels?

The label advises increased clinical or laboratory monitoring when semaglutide tablets are used with other oral drugs that have a narrow therapeutic index or that require clinical monitoring [1]. It reports no clinically significant effect on lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin [1]. Venlafaxine and duloxetine are not among the drugs named in those results, so the label gives no data on them.

On the enzyme side, semaglutide is broken down by proteolytic cleavage of the peptide backbone and beta-oxidation of its fatty acid side chain rather than by CYP enzymes, and has very low potential to inhibit or induce them [1]. Duloxetine is cleared by CYP1A2 and CYP2D6 and is itself a moderate CYP2D6 inhibitor [3]; venlafaxine depends on CYP2D6 to form its active metabolite [2]. Semaglutide is not part of those pathways.

Blood pressure: the numbers come from the SNRI labels

Both antidepressant labels call for blood pressure checks: the venlafaxine label says to monitor before starting treatment and regularly during treatment [2], and the duloxetine label says to check before starting and periodically [3]. The Rybelsus warnings section lists no blood pressure warning [1].

Venlafaxine's effect is dose related. In MDD trials at 75 to 375 mg/day, sustained hypertension (supine diastolic at least 90 mm Hg and at least 10 mm Hg above baseline on three visits) occurred in 19 of 705 patients, or 3%; the rates were 0.5% in generalized anxiety, 0.6% in social anxiety and 0.9% in panic disorder [2]. A rise of at least 15 mm Hg in supine diastolic pressure to 105 mm Hg or above occurred in 1.4% on venlafaxine versus 0.9% on placebo, and a rise of at least 20 mm Hg in supine systolic pressure to 180 mm Hg or above in 1% versus 0.3% [2]. Too few patients took more than 300 mg/day for the label to assess that range, and the labeled maximum for Effexor XR is 225 mg once daily [2].

A 1998 meta-analysis of original data from 3,744 depressed patients in controlled trials of venlafaxine against imipramine and/or placebo found small but statistically significant rises in supine diastolic pressure, an effect that was highly dose dependent and clinically significant only above 300 mg/day; venlafaxine did not worsen blood pressure control in patients who already had high blood pressure [4].

Duloxetine looks different at usual doses. In adult placebo-controlled trials the mean change was a rise of 0.5 mm Hg systolic and 0.8 mm Hg diastolic, against falls of 0.6 and 0.3 mm Hg on placebo, with no significant difference in sustained elevated blood pressure [3]. At 200 mg twice daily, about 3.3 times the maximum recommended dose, supine blood pressure rose 4.7 to 6.8 mm Hg systolic and 4.5 to 7 mm Hg diastolic, and pulse rose 5 to 6.8 beats per minute [3]. The label still says to check blood pressure before and periodically, and carries warnings about orthostatic hypotension, falls and syncope [3].

Serotonin syndrome: an SNRI warning, not a semaglutide one

The venlafaxine label states that SNRIs, including Effexor XR, can precipitate serotonin syndrome, that the risk rises with other serotonergic drugs and MAOIs, and that it can occur when the SNRI is used alone [2]. The drugs it names are triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, St. John's wort, other SNRIs and SSRIs, and MAOIs [2]. Signs listed include mental status changes such as agitation or hallucinations, autonomic instability such as tachycardia, labile blood pressure, sweating and hyperthermia, neuromuscular findings such as tremor, rigidity, myoclonus and hyperreflexia, seizures, and gastrointestinal symptoms [2]. The label says to discontinue the SNRI and any other serotonergic agents and begin supportive treatment if these occur [2].

Semaglutide is not among the drugs the venlafaxine label names, and the Rybelsus warnings section does not include serotonin syndrome [1][2].

If Rybelsus is being used for weight

Rybelsus is labeled for glycemic control and cardiovascular risk reduction in type 2 diabetes, not for weight loss [1]. Separately, the Effexor XR label says concomitant use with weight-loss agents is not recommended, and that the safety and efficacy of venlafaxine with weight-loss agents, including phentermine, have not been established [2]. The label gives phentermine as its example and does not name semaglutide or Rybelsus.